MEDICIS-PROMEDProject ID: 642889
MEDICIS-produced radioisotope beams for medicine
Gesamtkosten:EUR 2 829 269,88
EU-Beitrag:EUR 2 829 269,88
Aufruf zur Vorschlagseinreichung:H2020-MSCA-ITN-2014See other projects for this call
Finanzierungsprogramm:MSCA-ITN-ETN - European Training Networks
Pure accelerated radioisotope beams have been used for 50 years in fundamental physics R&D, e.g. for nuclear structure studies (pear shaped exotic nuclei, Nature 2013); CERN-ISOLDE plays a central role in developing accelerator technologies and fostering collaborative approaches to advance this field of isotope mass separation online. Our most recent contribution was the use of nanomaterial targets for more intense and reliable beam production, and laser ion sources for their purification (discovery of yet unknown 233Francium).
Radioisotopes are widely used for functional imaging in medicine, based on 99mTechnetium or on 18Fluorine. This field is expected to rapidly expand, when coupling imaging with new cancer treatments, with isotopes emitting different type of radioactivity, e.g. alpha particles. This is shown with the recently introduced 223Radium chloride (Xofigo®) used as a treatment drug in advanced bone cancers. However, either shortage in the supply of 99mTechnetium or lack of access to new radioisotope with adequate properties is a severe treat to develop personalized treatment that combine functional imaging and therapy.
Ovarian cancers have poor prognosis, are the second most frequent cancer for women and one of the deadliest. They are difficult to treat, because of possible presence of metastasis, and because this region is difficult to irradiate without collateral damages.
MEDICIS-PROMED will train a new generation of scientists to develop systems for personalized Medicine combining functional imaging and treatments based on radioactive ion beam mass-separation. This will be done across a coherent intersectorial multidisciplinary network with world-leading scientists in their field.
Subsystems for the development of new radiopharmaceuticals, of isotope mass separators at medical cyclotrons, and of mass separated 11Carbon for PET-aided hadron therapy will be specifically developed to treat the ovarian cancer.
EU-Beitrag: EUR 795 680,28
ROUTE DE MEYRIN CERN
1211 GENEVA 23
EU-Beitrag: EUR 273 287,88
OXFORD ROAD UNIVERSITY OF MANCHESTER OFFICE OF DIRECTOR OF FINANCE
M13 9PL MANCHESTER
EU-Beitrag: EUR 249 216,48
EU-Beitrag: EUR 262 875,60
Rue Diesel 20
01630 Saint Genis Pouilly
EU-Beitrag: EUR 476 712,72
AVENIDA ROVISCO PAIS 1
EU-Beitrag: EUR 258 061,32
Via Caminadella 16
EU-Beitrag: EUR 250 560
Oude Markt 13
EU-Beitrag: EUR 262 875,60
3.RUE DE L'EUROPE